Journal
MICROORGANISMS
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms10010127
Keywords
Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA); pneumococcal disease; 13-valent pneumococcal conjugate (PCV13) vaccine; community-acquired pneumonia; invasive pneumococcal disease
Categories
Ask authors/readers for more resources
This article reviews the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) and its extended studies, highlighting the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) in preventing pneumonia and invasive pneumococcal disease in older adults. It provides valuable insights for the assessment of adult pneumococcal vaccination.
The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) evaluated older adult pneumococcal vaccination and was one of the largest vaccine clinical trials ever conducted. Among older adults aged >= 65 years, the trial established 13-valent pneumococcal conjugate vaccine (PCV13) efficacy in preventing first episodes of bacteremic and nonbacteremic pneumococcal vaccine serotype (VT) community acquired pneumonia (CAP), and of vaccine serotype invasive pneumococcal disease (VT-IPD). Since the publication of the original trial results, 15 additional publications have extended the analyses. In this review, we summarize and integrate the full body of evidence generated by these studies, contextualize the results in light of their public health relevance, and discuss their implications for the assessment of current and future adult pneumococcal vaccination. This accumulating evidence has helped to better understand PCV13 efficacy, serotype-specific efficacy, efficacy in subgroups, the interpretation of immunogenicity data, and the public health value of adult PCV vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available